Loading...
Loading...
MIST| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | -0.0M |
| Operating Expense | 16.4M |
| Operating I/L | -16.4M |
| Other Income/Expense | 0.4M |
| Interest Income | 1.2M |
| Pretax | -16.0M |
| Income Tax Expense | 1.2M |
| Net Income/Loss | -16.0M |
Milestone Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development and commercialization of cardiovascular medicines. The company's primary focus is on the development of etripamil, a novel channel blocker currently in Phase III clinical trials for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, with additional Phase II trials for the treatment of atrial fibrillation and rapid ventricular rate. Milestone Pharmaceuticals has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil for prophylactic and therapeutic uses in humans.
